HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zacks, D. N. Articles by Miller, J. W. Search for Related Content PubMed PubMed Citation Articles by Zacks, D. N. Articles by Miller, J. W.

Verteporfin Photodynamic Therapy in the Rat Model of Choroidal Neovascularization: Angiographic and Histologic Characterization

¹ From the Retina Service and Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.

PURPOSE. To develop a model of verteporfin photodynamic therapy (PDT) for experimental choroidal neovascularization CNV in the rat.

METHODS. A laser injury model was used to induce experimental CNV in rats. The transit and accumulation of the photosensitizer verteporfin was assessed angiographically in CNV lesions, to determine the optimal time for delivery of light energy. The CNV lesions were then treated with verteporfin PDT, with two doses of verteporfin (3.0 and 6.0 mg/m²) and four activating doses of light energy (10, 25, 50, and 100 J/cm²). Closure of the CNV was assessed both angiographically and histologically. Verteporfin PDT was also performed on areas of normal choroid and retina at the two verteporfin doses and four light energy doses. The effect of these treatments on these structures was also assessed angiographically and histologically.

RESULTS. Peak verteporfin intensities in the CNV were detected at 15 to 20 minutes after intravenous injection. Rates of closure of the CNV varied as a function of the dose of verteporfin and of the activating light energy. Angiographic closure of the CNV correlated with damage to the neovascular complex, as seen with light and electron microscopy. Damage to areas of normal choroid and retina treated with verteporfin PDT also varied as a function of the verteporfin and light energy doses.

CONCLUSIONS. Verteporfin PDT for experimental CNV in the rat is a feasible, effective, and reproducible model that can be used for testing the efficacy of adjunctive therapy to verteporfin PDT.

This article has been cited by other articles:

				A Odergren, P V Algvere, S Seregard, and A Kvanta A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration Br. J. Ophthalmol., June 1, 2008; 92(6): 757 - 761. [Abstract] [Full Text] [PDF]

				M. Berdugo, R. A. Bejjani, F. Valamanesh, M. Savoldelli, J.-C. Jeanny, D. Blanc, H. Ficheux, A. Scherz, Y. Salomon, D. BenEzra, et al. Evaluation of the New Photosensitizer Stakel (WST-11) for Photodynamic Choroidal Vessel Occlusion in Rabbit and Rat Eyes Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1633 - 1644. [Abstract] [Full Text] [PDF]

				A. Matsubara, T. Nakazawa, K. Noda, H. She, E. Connolly, T. A. Young, Y. Ogura, E. S. Gragoudas, and J. W. Miller Photodynamic Therapy Induces Caspase-Dependent Apoptosis in Rat CNV Model Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4741 - 4747. [Abstract] [Full Text] [PDF]

				H. She, T. Nakazawa, A. Matsubara, T. Hisatomi, T. A. Young, N. Michaud, E. Connolly, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2268 - 2277. [Abstract] [Full Text] [PDF]

				D. M. Paskowitz, K. M. Donohue-Rolfe, H. Yang, D. Yasumura, M. T. Matthes, K. Hosseini, C. M. Graybeal, G. Nune, M. A. Zarbin, M. M. LaVail, et al. Neurotrophic Factors Minimize the Retinal Toxicity of Verteporfin Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 430 - 437. [Abstract] [Full Text] [PDF]

				R. Tzekov, T. Lin, K.-M. Zhang, B. Jackson, A. Oyejide, W. Orilla, A. D. Kulkarni, B. D. Kuppermann, L. Wheeler, and J. Burke Ocular Changes after Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 377 - 385. [Abstract] [Full Text] [PDF]

				D. M. Paskowitz, G. Nune, D. Yasumura, H. Yang, R. B. Bhisitkul, S. Sharma, M. T. Matthes, M. A. Zarbin, M. M. LaVail, and J. L. Duncan BDNF Reduces the Retinal Toxicity of Verteporfin Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 4190 - 4196. [Abstract] [Full Text] [PDF]

				R. Z. Renno, Y. Terada, M. J. Haddadin, N. A. Michaud, E. S. Gragoudas, and J. W. Miller Selective Photodynamic Therapy by Targeted Verteporfin Delivery to Experimental Choroidal Neovascularization Mediated by a Homing Peptide to Vascular Endothelial Growth Factor Receptor-2 Arch Ophthalmol, July 1, 2004; 122(7): 1002 - 1011. [Abstract] [Full Text] [PDF]

				Y. Ming, P. V. Algvere, A. Odergren, L. Berglin, I. van der Ploeg, S. Seregard, and A. Kvanta Subthreshold Transpupillary Thermotherapy Reduces Experimental Choroidal Neovascularization in the Mouse without Collateral Damage to the Neural Retina Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1969 - 1974. [Abstract] [Full Text] [PDF]

				U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G. O. H. Naumann Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 3, and Pigment Epithelium-Derived Factor Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4473 - 4480. [Abstract] [Full Text] [PDF]